What the duplicate discount rule forbids, what the Medicaid Exclusion File records, what each choice costs on the same units, and why managed care is a separate question.
A carve-in site buys drugs for its Medicaid fee-for-service patients at 340B and, where the state pays acquisition cost, hands the discount to the state; a carve-out site buys them outside 340B. With 720 Medicaid units out of 2,400 and a $226 discount per unit, $162,720 leaves the program either way and $379,680 stays.
Worked in full in The 340B Program Handbook by Julian R. Sterling, with every figure reproduced in a free workbook.Get the DRM-free PDF, $19.99 →
Two federal programs can discount the same drug. Under the Medicaid drug rebate program, a manufacturer pays the state a rebate on units that Medicaid paid for. Under 340B, the manufacturer sells the unit to the covered entity at or below the ceiling price, upfront. As read in November 2026, 42 U.S.C. 256b(a)(5)(A) forbids a covered entity to request Medicaid payment for a drug subject to a Medicaid rebate if the drug was bought at the 340B price: the manufacturer should not give both discounts on one unit. The same section lets the Secretary and the manufacturer audit the records that bear on that rule, and if a violation is found after audit, notice and hearing, the entity is liable to the manufacturer for the discount it received (paragraphs (C) and (D)).
The rule works unit by unit, so the remedy does too. Either the entity uses 340B for its Medicaid fee-for-service patients and says so, so that the state does not claim a rebate on those units, or it does not use 340B for them at all. That is the choice between carve-in and carve-out.
HRSA's page on the duplicate discount prohibition, read in November 2026, describes the mechanism. At enrollment, each covered entity site tells HRSA whether it will use 340B drugs for its Medicaid fee-for-service patients (carve-in) or buy those drugs through other mechanisms (carve-out). A carve-in site lists each state Medicaid program it bills and the billing numbers it uses, and the Medicaid Exclusion File, the MEF, reflects those listings. A state can then leave the matching claims out of its rebate requests.
A carve-in site buys the Medicaid fee-for-service unit at the 340B price and bills Medicaid for it. What the state then pays is a matter of state rules. Federal regulations at 42 CFR 447.502 and 447.512 define actual acquisition cost and the professional dispensing fee used in fee-for-service payment, but how a given state pays for a drug bought at 340B was not confirmed for any state when this page was written. Where a state pays the entity its 340B acquisition cost plus a dispensing fee, the entity recovers its cost and the fee, not the discount: the discount passes to the state. In a savings report, that amount is a deduction in the bridge from gross to net savings, taken once.
Carve-in keeps one inventory and one rule at the site. Its risks are administrative: an outdated MEF listing, a billing number missing from it, or a claim billed above acquisition cost where the state expects acquisition cost.
A carve-out site never buys Medicaid fee-for-service units at 340B. It buys them on another account (for a hospital under the GPO prohibition, a non-GPO account) and the state may claim its rebate as usual. The entity gives up the 340B discount on those units instead of passing it on. Its risk mirrors carve-in: a Medicaid unit that slips into a 340B replenishment, through a split-billing file or a TPA that did not see the payer, is a duplicate discount and a repayment owed to the manufacturer.
A sample site, not the book's case, dispenses 2,400 eligible units of one drug in a year. 30 percent of them, 720 units, are paid by Medicaid fee-for-service. The gap between WAC and the 340B price is $226 per unit, and the state in this example pays carved-in drugs at acquisition cost plus a dispensing fee. Every figure is a teaching assumption.
| Line | Carve-in | Carve-out |
|---|---|---|
| Eligible units in the year | 2,400 | 2,400 |
| Medicaid fee-for-service units (30 percent) | 720 | 720 |
| Medicaid units bought at 340B | 720 | 0 |
| Discount on the Medicaid units | $162,720 passed to the state | $162,720 not captured |
| Savings kept on the other 1,680 units | $379,680 | $379,680 |
On these assumptions the two choices cost the same: $162,720 of discount leaves the program under both, and $379,680 stays on the 1,680 other units. The comparison moves only when an assumption moves. If the state paid a carved-in drug above acquisition cost, carve-in would keep part of the discount. If dispensing fees, inventory work or audit exposure differ between the two set-ups, those costs decide. The figures show what is at stake; the state's rules and the program's controls decide which way is cheaper.
The trap: when two sites of one entity make different choices, counting the Medicaid discount as lost savings at the carve-out site and again as a deduction at the carve-in site, or applying one site's share to the other. Each site deducts its own Medicaid units once, in its own channel of the bridge.
The MEF does not reach managed care. As read in November 2026, 42 U.S.C. 1396r-8(j)(1) provides that covered outpatient drugs dispensed by health maintenance organizations, including Medicaid managed care organizations, are not subject to the Medicaid rebate requirements if they are subject to 340B discounts. How each state identifies 340B claims in managed care, whether by claim modifiers, files or another method, was not confirmed for any state here. A program would therefore treat managed care as its own policy question, settled with the state agency and the plans where possible, and ask its counsel rather than extend its fee-for-service choice by default.
The case is fictional: Talbryn Regional Medical Center, a 240-bed private non-profit hospital in the 340B Program as a disproportionate share hospital, with three eligible sites, an in-house retail pharmacy and four contract pharmacies served through one TPA, measured for calendar 2025. Every price, volume, fee and rate of the case is a teaching assumption, not a market figure, and the facts of your own program govern.
Talbryn carves in at its own sites and carves out at its four contract pharmacies. At its own sites, the carve-in passes $956,399.00 of discount to the state, the largest deduction of its bridge. At the contract pharmacies, the carve-out keeps 765 claims out of 340B, so no duplicate discount should arise there. Its self-audit still finds one: a Medicaid fee-for-service claim at a carve-out contract pharmacy that was replenished at 340B. And when 20 percent more of the in-house units are Medicaid fee-for-service, with the same total units, net savings fall by $191,279.80.
Rules are described as read in November 2026 from 42 U.S.C. 256b(a)(5), 42 U.S.C. 1396r-8(j)(1), 42 CFR 447.502 and 447.512, and HRSA's Office of Pharmacy Affairs pages on the duplicate discount prohibition and on program integrity, and they change. No state rule is described. This page is education, not legal advice: ask the program's counsel how any rule applies to your program.
A unit discounted twice: bought at the 340B price and also counted for a Medicaid rebate that the manufacturer pays to the state. As read in November 2026, 42 U.S.C. 256b(a)(5)(A) forbids it, and a finding after audit makes the entity liable to the manufacturer.
A carve-in site uses 340B drugs for its Medicaid fee-for-service patients and is listed on the Medicaid Exclusion File; a carve-out site buys those drugs outside 340B. The choice is made site by site.
No. As read in November 2026, HRSA's page says the MEF applies to fee-for-service only. Managed care claims follow each state's own method, which a program should confirm with the state and its counsel.
On the first day of the next quarter, if HRSA approves it before the quarterly snapshot at 12:01 a.m. Eastern time on the 16th day of the month before the quarter. HRSA generally makes no retroactive change.
It depends on the state's payment rule and on the program's controls. Where the state pays carved-in drugs at acquisition cost, the discount on the Medicaid units leaves the program either way, as in the example above.
This article is one step of The 340B Program Handbook. The book follows one hospital through a full 340B year: three eligible sites and one that had to wait, the patient definition applied claim by claim, three purchase accounts and an accumulator, a carve-in and a carve-out, four contract pharmacies and their TPA, the bridge from potential to net savings, a manufacturer restriction, a rebate scenario and a self-audit that ends in a self-disclosure.
Paperback PDF edition, $19.99 Book page and free files
Free: the 340B savings calculator in Excel.
Case figures computed by the book's model; the hospitals and pharmacies are fictional and every price, fee and rate is a teaching assumption. Figures checked on 20 November 2026. Rules described as read on the dates given; not legal advice.